908
908 is a company.
Active
Updated: ·
About
Technology company
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at 908.
908 is a company.
Technology company
Key people at 908.
908 Devices Inc. (NASDAQ: MASS) is a commercial-stage technology company founded in 2012 that develops purpose-built handheld and desktop mass spectrometry (Mass Spec) devices for point-of-need chemical analysis.[1][2][3][5] These devices address critical challenges in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets by enabling rapid interrogation of unknown solid, liquid, vapor, or aerosol materials, serving customers in the United States, Europe, the Middle East, Africa, Asia Pacific, and the rest of the Americas.[2][3][4] Key products include the handheld MX908 for trace-level detection in forensics (e.g., chemicals, explosives, drugs), desktop Rebel and Maverick for real-time bioprocess monitoring (e.g., glucose, lactate, biomass), and others like Maven, Trace C2, and ZipChip for bioprocessing and sample analysis.[2][3] The company is executing "908 Devices 2.0," a strategic pivot to solidify leadership in these areas, with demonstrated revenue growth from 2020 to 2023 and institutional ownership at 73.47%.[1][4]
908 Devices was established in 2012 in Boston, Massachusetts, by co-founders Dr. Kevin J. Knopp (current CEO and President) and Dr. Michael J. Ramsey, leveraging expertise in mass spectrometry to create portable analytical tools.[1][2] The idea emerged from a need for accessible, point-of-need devices that combine Mass Spec with software automation and machine learning, moving beyond traditional lab-bound equipment.[5] Early milestones include strategic collaborations like with Agilent Technologies to expand capabilities, an IPO that fueled R&D and market growth, and consistent revenue increases validating product demand.[1] Leadership has evolved with figures like E. Kevin Hrusovsky as Independent Chairman since 2013 and recent additions such as Michele M. Leonhart as Independent Director in 2024.[2]
908 Devices rides the wave of point-of-need diagnostics and portable analytics, fueled by rising demands in bioprocessing for faster drug development, forensics amid the opioid crisis (e.g., fentanyl detection), and defense against chemical threats.[3][5] Timing aligns with post-pandemic biopharma expansion and regulatory pushes for real-time manufacturing control, where traditional lab Mass Spec falls short in speed and mobility.[2] Market forces like industrial biotech growth and global security needs favor its devices, which lower barriers to advanced analysis and enable on-site decisions, influencing ecosystems by accelerating research workflows and supporting scalable biomanufacturing.[1][4]
908 Devices is poised to deepen its "2.0" pivot through expanded bioprocessing adoption and forensics tools, potentially driving further revenue via new markets and AI enhancements.[1] Trends like AI-integrated analytics, personalized medicine, and synthetic biology will shape its path, amplifying demand for real-time, portable Mass Spec amid biopharma's shift to continuous manufacturing. Its influence may grow by setting standards in point-of-need tech, evolving from niche innovator to essential player in health, safety, and defense—building on its mission to deliver accessible tools that tackle invisible threats.[5]
Key people at 908.